CS
ABBV icon

Credit Suisse’s AbbVie ABBV Stock Holding History

Credit Suisse’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-774,400
Closed -$105M – 3563
2021
Q4 		$105M Buy
774,400
+71,600
+10% +$8.46M 0.06% 345
2021
Q3 		$75.8M Sell
702,800
-35,100
-5% -$4.01M 0.04% 469
2021
Q2 		$82.9M Sell
737,900
-280,500
-28% -$31.6M 0.04% 454
2021
Q1 		$110M Sell
1,018,400
-50,200
-5% -$5.37M 0.06% 377
2020
Q4 		$115M Sell
1,068,600
-75,800
-7% -$7.28M 0.06% 367
2020
Q3 		$100M Buy
1,144,400
+531,900
+87% +$50.1M 0.06% 344
2020
Q2 		$60.1M Sell
612,500
-83,400
-12% -$7.34M 0.04% 456
2020
Q1 		$53M Sell
695,900
-90,100
-11% -$7.67M 0.05% 417
2019
Q4 		$69.6M Buy
786,000
+167,200
+27% +$13.9M 0.05% 402
2019
Q3 		$46.9M Buy
618,800
+5,200
+0.8% +$357K 0.04% 481
2019
Q2 		$44.6M Buy
613,600
+146,000
+31% +$11.5M 0.04% 492
2019
Q1 		$37.7M Buy
467,600
+452,900
+3,081% +$37.1M 0.03% 539
2018
Q4 		$1.35M Buy
14,700
+3,000
+26% +$264K ﹤0.01% 2548
2018
Q3 		$1.11M Hold
11,700
– – ﹤0.01% 2790
2018
Q2 		$1.08M Buy
+11,700
New +$1.14M ﹤0.01% 2960
2018
Q1 		– Sell
-50,000
Closed -$4.84M – 3945
2017
Q4 		$4.84M Buy
+50,000
New +$4.71M ﹤0.01% 1805
2017
Q3 		– Sell
-100,000
Closed -$7.25M – 4165
2017
Q2 		$7.25M Buy
100,000
+60,000
+150% +$4.03M 0.01% 1392
2017
Q1 		$2.61M Buy
+40,000
New +$2.51M ﹤0.01% 2154
2016
Q2 		– Sell
-57,300
Closed -$3.27M – 4186
2016
Q1 		$3.27M Sell
57,300
-112,700
-66% -$6.28M ﹤0.01% 1823
2015
Q4 		$10.1M Buy
170,000
+135,000
+386% +$7.78M 0.01% 1142
2015
Q3 		$1.9M Buy
+35,000
New +$2.28M ﹤0.01% 2295
2015
Q2 		– Sell
-115,000
Closed -$6.73M – 4511
2015
Q1 		$6.73M Buy
+115,000
New +$6.95M 0.01% 1444

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Credit Suisse's ABBV Position: Q1 2024 in Review

Credit Suisse increased its AbbVie (ABBV) stake by 3.9% in Q1 2024, buying an estimated $17.5M and bringing the position to 2,736,828 shares worth $498M. The position accounts for 0.48% of the portfolio, ranked #28.

Credit Suisse first reported a position in ABBV in Q2 2013 and has held it in 44 quarters since. The position peaked at $542M in Q1 2022. 3,379 funds tracked by Wall St. Rank hold ABBV as of Q1 2024.

  • Credit Suisse held 2,736,828 shares of AbbVie worth $498M as of Q1 2024.
  • Credit Suisse bought 101,696 AbbVie shares in Q1 2024, an estimated $17.5M.
  • AbbVie made up 0.48% of Credit Suisse's portfolio in Q1 2024, its #28 holding.
  • Credit Suisse first reported a position in AbbVie in Q2 2013 and has held it in 44 quarters since.
  • Credit Suisse's AbbVie position peaked at $542M in Q1 2022.
  • 3,379 funds tracked by Wall St. Rank held AbbVie as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.